logo
Barry FitzGerald: Katanning ticks all the boxes for an Ausgold re-rate

Barry FitzGerald: Katanning ticks all the boxes for an Ausgold re-rate

Herald Sun06-06-2025
'Garimpeiro' columnist Barry FitzGerald has covered the resources industry for 35 years. Now he's sharing the benefits of his experience with Stockhead readers.
After its dramatic rise in the opening months of the year to record levels, the Aussie gold price has settled into a bit of a groove around the $5,200/oz level.
Nothing wrong with that. It's a fantastic price and delivers fat margins to even our highest cost gold mines.
And it is not to suggest that gold can't take off again and set new highs or fall significantly for that matter.
The observation is that for the last six weeks or so the Aussie price has been as steady as it could be in these turbulent times.
It means that share prices of ASX-listed gold producers and developers have also gone into a sideways trading pattern. Need to differentiate
So more than has been the case in recent times when gold took off to record levels, the producers and developers now need to differentiate themselves from the pack with strong newsflow of the re-rating inducing type.
It means that if the gold price continues to trade sideways, the stock involved has a reason to go higher. Alternatively, if the gold price heads south, the damage to the stock could be more limited than it would have been otherwise.
Taking all that on board, Garimpeiro had a look at his calendar during the week to find which of the gold producers/developers have re-rating event(s) on the horizon. Ausgold stands out
Ausgold (ASX:AUC) stood out for the pending release this month of a definitive feasibility study (DFS) into the development of its Katanning gold project, a three-hour drive from Perth in WA's southwest Yilgarn region.
Katanning is one of the biggest undeveloped gold deposits in the country at 3.04 million ounces and has previously been scoped as having the potential to produce 136,000 ounces annually from open-cut ore sources for more than 10 years.
All-in sustaining costs were put at $A1,549 and preproduction capital costs weighed in at just under $300m. But those are 2023 figures and things will have changed, including the reserve component of the resource thanks to infill drilling work.
Gold prices have increased dramatically since those 2023 figures but so have construction costs. Having said that, the expectation is that the DFS will confirm Katanning as a very robust project with a super quick capex payback capability.
Take that and the scale of the project – production in the early years will be higher still because initial higher grade ores - and Ausgold's $240 million market cap at 67c share looks to be on the mean side of things.
The company has the lowest resource ounce valuation metric of its peer group for no apparent reason, except perhaps the project has been in the works since 2010 under Ausgold ownership.
So the story of the resource growth since, and the pending release of the DFS leading into a development decision by year end, has been overlooked to a large degree by the market on a fatigue basis alone. Katanning momentum
Momentum for Katanning is now the order of the day under John Dorward, Ausgold's executive chairman who arrived on the scene in May last year.
A can-do sort of guy, Dorward was the former president and CEO of TSX-listed Roxgold, a West African gold group acquired by fellow Canadian Fortuna Silver Mines in an all-scrip deal worth $US884 million in 2021.
Two weeks in the job at Ausgold and Dorward put Katanning on the development pathway by pulling in $38 million in equity, including $1m from his own pocket.
That is being spent getting to the DFS stage and on a three-pronged strategy of establishing a bigger mining reserve component in the mineral resource estimate, extending the scale of the resource and making regional gold discoveries. Morgans' 94c target
Morgans' veteran analyst Chris Brown has a 12-month price target on the stock of 94c.
'Our expectation is that delivery of a DFS broadly confirming or improving on the preliminary feasibility study, and employing a higher gold price, should prove positive for the share price,' Brown said.
He also flagged that a final investment decision on a project development – expected by the end of the year - should also prove positive depending on the terms of the project's financing package.
''Our valuation will likely lift with the delivery of the DFS, and again when the final investment decision is taken,'' Brown said.
The views, information, or opinions expressed in this article are solely those of the columnist and do not represent the views of Stockhead. Stockhead does not provide, endorse or otherwise assume responsibility for any financial product advice contained in this article.
Originally published as Barry FitzGerald: Katanning ticks all the boxes for an Ausgold re-rate
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Doubling up: How ASX biotechs are multiplying their impact
Doubling up: How ASX biotechs are multiplying their impact

Mercury

time5 hours ago

  • Mercury

Doubling up: How ASX biotechs are multiplying their impact

ASX companies finding smarter ways to stretch value of existing assets and launch into broader clinical areas LTR Pharma leveraging proven intranasal platform for erectile dysfunction treatment to target non-invasive relief for patients with swallowing difficulties From concussion to Alzheimer's the CogState Cognigram digital cognitive assessment system is used by physicians to monitor brain function As global biotech faces increasing pressure to deliver more with less, several ASX-listed healthcare companies are working to find smarter ways to stretch the value of their existing assets. Whether it's repurposing a drug delivery platform, extending the reach of a diagnostic tool or developing next-generation compounds that act on the same biological pathway to treat other conditions, these companies are using proven science as a launchpad into broader clinical territory. The strategy is playing out globally, with Novo Nordisk and Eli Lilly providing high-profile examples of repurposing GLP-1 drugs – originally developed for type 2 diabetes – for weight loss. Blockbusters like Ozempic/Wegovy (Novo Nordisk) and Mounjaro/Zepbound (Eli Lilly) are now reshaping treatment for obesity and related conditions. It's a compelling demonstration of how one well-validated mechanism of action can be leveraged across multiple disease areas in turn lowering development risk, tapping into existing safety and efficacy data, and accelerating time to market. For ASX healthcare companies navigating tighter capital conditions, similar strategies are proving to be a smart and resourceful way to unlock broader clinical value from their existing platforms. LTR Pharma rises above ED with nasal spray tech targeting broader conditions Developer of a nasal spray treatment for erectile dysfunction (ED), LTR Pharma (ASX:LTP) has turned to a secondary program using its innovative intranasal delivery platform but this time for oesophageal motility disorders (OMD). In May, LTR Pharma announced it had inked a collaborative development agreement with US-based Strategic Drug Solutions (SDS) to develop Oroflow a spray for OMD – a group of conditions that cause impaired swallowing (dysphagia). The program leverages LTR's proven proprietary intranasal delivery platform and foundational work from its Spontan and Roxus ED treatments to target rapid symptom relief for patients with swallowing difficulties, potentially offering a non-invasive alternative to current treatments. Oroflow aims to deliver relief in 10 minutes, bypassing swallowing barriers and offering a compelling althernative to treatments including invasive procedures such as pneumatic dilation, surgery, or botulinum toxin injections. LTR Pharma is addressing a $4.5 billion OMD market projected to reach $8.1 bn by 2034 with the company announcing in its latest quarterly report that proof-of-concept testing preparations were underway. LTR Pharma executive chairman Lee Rodne said Oroflow represented an exciting expansion of its nasal spray platform. "For patients with swallowing difficulties, oral medications present obvious challenges for patients," he said. "Our nasal spray technology is designed to offer a patient-friendly solution that avoids the need to swallow medications, have surgery or undergo other problematic treatments while providing rapid symptom relief. Neuren targeting broad set of neurological conditions Neuren Pharmaceuticals (ASX:NEU) is another standout. The company and US partner Acadia was in 2023 granted the first US Food and Drug Administration (FDA) approval for a drug to treat Rett syndrome, a rare neurological disorder mostly affecting girls and emerging in infancy. Trofinetide, marketed as Daybue, is a synthetic analog of part of the hormone insulin-like growth factor 1 (IGF-1), which is a potent regulator of central nervous system development. Neuren is now advancing NNZ-2591, which also targets IGF-1. Building on the scientific foundation of trofinetide, NNZ-2591 is structurally optimised to improve brain penetration, enhance tolerability, and expand therapeutic reach across a broader set of neurodevelopmental conditions. Using a strategy that targets multiple indications from one compound, Neuren aims to accelerate development while reducing R&D expenses. Currently in phase II trials, NNZ-2591 could open new treatment avenues for other underserved neurodevelopmental conditions like Phelan-McDermid, Angelman, and Pitt-Hopkins syndromes. The company is preparing to start a phase III study of NNZ-2591 for its most advanced program Phelin McDermid. It also plans to consult with the FDA this year to establish a clinical path for NNZ-2591 to treat hypoxic-ischemic encephalopathy (HIE), which results from a baby's brain not getting enough oxygen or blood flow before, or shortly after, birth. "We believe the mechanism of action of NNZ-2591 can be broadly applicable to neurodevelopmental disorders, independent of the genetic origin," CEO Jon Pilcher told Stockhead. "We are striving to be successful in multiple settings, for the benefit of both the impacted families and our shareholders." Tracking cognition from concussion to Alzheimer's From footy fields to neurology clinics, the CogState (ASX:CGS) Cognigram digital cognitive assessment system is used by physicians to monitor key aspects of brain function – including processing speed, attention, visual learning, working memory and executive function. The test can assess cognition at a single point in time or track changes over multiple assessments. You may have heard of it referred to as the Cogstate concussion test in footy coverage. However, Cognigram has since evolved into a widely used tool in healthcare and research. Cogstate is riding a wave of global demand for cognition-related clinical trials, particularly in the race to treat Alzheimer's disease and related dementias. The company recently upgraded its financial guidance for FY25, reflecting strong performance and improved outlook across key financial metrics. Full-year profit before tax is forecast to be in the range of $12-14m, an improvement of 69% to 97% on FY24. "We are now using Cognigram, which is the same cognitive assessment used to assess AFL footballers for concussion, to prescreen for clinical trials in the earlier stages of Alzheimer's," CEO Brad O'Connor told Stockhead. "We have a contract with a large pharmaceutical company screening for 20,000 patients in the community to find those that might be appropriate to include in their very early stage Alzheimer's trials. At Stockhead, we tell it like it is. While LTR Pharma is a Stockhead advertiser, the company did not sponsor this article. Originally published as Doubling up: How ASX biotechs are multiplying their impact

Harvest Tech posts 135% revenue growth
Harvest Tech posts 135% revenue growth

Herald Sun

time6 hours ago

  • Herald Sun

Harvest Tech posts 135% revenue growth

Don't miss out on the headlines from Stockhead. Followed categories will be added to My News. Harvest Technology Group records 135% YoY increase in quarterly revenue Raises $970,000 through mix of debt and convertible note instruments Dual lists on Frankfurt Stock Exchange to broaden investor base Special Report: Harvest Technology Group has recorded a 135% YoY increase in quarterly revenue, reaching $1.1 million in Q4 FY25, with the company expecting to exceed $3.5 million in total revenue for the full year. Cash receipts for remote communications tech-solutions provider Harvest Technology Group (ASX:HTG) for the June quarter came in at $631,000 with net cash inflows of $127,000. Net operating cash outflows for the quarter totalled $662,000 including $570,000 in R&D, $205,000 in staff, $17,000 in sales and marketing, $371,000 in corporate and administration, $105,000 in interest and $25,000 in other costs. HTG strengthened its balance sheet during the quarter, raising $970,000 (before costs) through a mix of debt and convertible note instruments including: $450,000 in unsecured convertible notes launched on June 30; $130,000 in secured convertible notes launched on June 27; and $390,000 short-term loan from managing director. After quarter end, HTG received a further $530,000 in funding in July through additional convertible notes and another loan from the managing director. In June HTG said it was tracking one year ahead of its pathway-to-profit plan as it focused on achieving a positive EBITDA before July 2026. As of June 30, HTG had $723,000 cash. Listing on Frankfurt Stock Exchange In a significant step toward expanding its international presence, HTG listed its shares on the open market segment of the Frankfurt Stock Exchange in April 2025. The dual listing is expected to broaden the investor base and increase visibility across European capital markets, with the company already experiencing an increase in trading volumes across both exchanges. In other key developments during the June quarter, HTG appointed Hugh Bickerstaff as sales and marketing director and strategic advisor. Bickerstaff brings deep expertise in founding and scaling some of Australia's fastest-growing technology businesses and is an experienced mentor in the sector. Start of Project Neon and new customer wins HTG also started project Neon, an Edge AI-enabled solution aimed at improving real-time decision-making in remote environments. The company secured new customer wins including two subsea services clients, with initial hardware sales and software subscriptions scheduled to begin in Q1 FY26. Additionally, the company expanded deployments across an existing customer fleet, unlocking further hardware sales and an uplift in recurring revenue from software. HTG continued engagement with a European defence customer via its Australian channel partner and began deploying its Nodestream technology across a new uncrewed surface vessel fleet in the Middle East. Enhancements to Nodestream platform In a major product milestone, HTG successfully integrated its Autopilot and Nodestream systems into a single, IP-rated enclosure. The robust weatherproof design simplifies installation and reduces the equipment footprint for deployment on autonomous vehicles and maritime vessels. The company also delivered significant improvements to its Nodestream platform during the quarter including a doubling of available data channels from 10 to 20, enabling more data-intensive operations. Additionally, the user interface has been overhauled to provide a more intuitive and efficient user experience. A comprehensive user permissions framework was introduced in Nodestream Live, improving access control and collaboration across distributed teams. This article was developed in collaboration with Harvest Technology Group, a Stockhead advertiser at the time of publishing. This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions. Originally published as Harvest Tech posts 135% quarterly revenue surge

Tech firm Atlassian axes 150 staff over video, says they won't be replaced by AI
Tech firm Atlassian axes 150 staff over video, says they won't be replaced by AI

Herald Sun

time6 hours ago

  • Herald Sun

Tech firm Atlassian axes 150 staff over video, says they won't be replaced by AI

Aussie tech firm Atlassian has come under fire for axing 150 staff while shelling out tens of millions of dollars on its F1 title sponsorship. Billionaire CEO and founder Mike Cannon-Brookes appeared in a pre-recorded video to staff, announcing 150 of them – including 44 in Australia – would be losing their jobs. Cannon-Brookes appeared dressed in a hoodie and speaking from his home office in the video - which was titled 'Restructuring the CSS Team: A Difficult Decision for Our Future' - in an address some staff felt was 'frank and cold'. Reports from staff claimed termination emails arrived for the unlucky staff 15 minutes later, as their laptops were blocked from company systems. The cuts are understood to be to customer service roles, with Atlassian claiming improvements to its systems meant there would be fewer complaints to deal with. A statement from the Sydney-based tech firm said the 'roles are not being replaced by AI'. 'We made this decision after implementing improvements to the customer experience across our platform and tools, resulting in a significant reduction in support needs,' the statement said. 'While we're proud of this momentum, it leaves us with more capacity than needed to deliver strong customer support. 'These improvements include reducing the time spent on support tickets with more efficient ways to route work to the right experts who can resolve issues more quickly, better identification and resolution of error codes and more.' Atlassian said sacked staff would receive 'a generous severance package, healthcare benefits for them and their families, six months access to our EAP and mental health services, visa support if needed, internal mobility and outplacement services'. The video came hours after co-founder Scott Farquhar was praising the benefits of AI during a National Press Club of Australia address. 'The scale of the opportunity and risks of missing out demand a new kind of partnership – one that moves at the speed of technology, not at the speed of bureaucracy,' he said. When asked about the job cuts, Mr Farquhar said there 'will be jobs changes' as a result of AI but 'if, as a nation we want to stick and have the jobs of the past, that is not a good plan for us'. 'In these times, or any time, we should be helping our employees to make the transition at a company level but also at a national level,' he said. 'Particularly in Australia, I feel very privileged and blessed that we live in a nation that has a very strong social safety net and very strong skill training and opportunities for our people to re-skill into new areas.' The news of the axings was met online with contempt from tech workers, who lambasted the move as 'out of touch', with others criticising Mr Cannon-Brookes for buying a private jet. 'Using AI for business support is kinda stupid, one lost customer could cost way more,' said one disgruntled user. 'The billions they make personally means they could just absorb those 150 heads easily without them even putting a bump on their bottom line,' said another. 'If you have the cash to sponsor an F1 team and then sack people you're an asshole.' The company has not revealed what it paid for its 10-year stake in UK-based Atlassian Williams Racing, but marketing experts say a title sponsorship generally costs upwards of $90m a year. The deal means Atlassian's logo has been splashed on the FW47 race cars being driven by Alex Albon and Carlos Sainz, meaning it will be seen by a television audience of more than 1.55 billion viewers, plus billions more online. Atlassian has been contacted for comment. Shares in Atlassian, which is listed on the US-based Nasdaq, dipped 1.44 per cent after news of the job cuts broke, trading at $197.19 on Thursday, down from $200.05 on the previous day's market close. Despite the cuts, the company was still advertising 345 open positions globally on Thursday morning. It employs more than 13,000 people worldwide. Atlassian is scheduled to release its full-year results next Thursday. The company is currently building a new Australian headquarters near Sydney's Central Station, which it will house the bulk of its local staff. Other staff work remotely across Australia. Originally published as Atlassian savaged for 'frank and cold' video sacking as company spends millions on F1 sponsorship

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store